Resource Type: Blog

It’s been an exciting and productive annual meeting for the Society for Immunotherapy of Cancer (SITC) 2017, full of ground-breaking science to share when back in the lab. For those…

Your data doesn’t fit in a box Gone are the days of assay-specific data analysis. nSolver 4.0 is analyte focused and less assay restricted. This means that any combination of…

We love that you’re here. Here’s why you’re going to love it, too: Fun-size articles on nSolver & Advanced Analysis. In between scientific papers, grant applications, and your other lengthy…

Immune checkpoint inhibitors (ICI) have emerged as powerful tools against cancer but in some cases have caused inflammation of organ systems that contributed to morbidity or mortality in patients. The…

Part one of this four-part series looked at how host, tumor, and environmental factors shape tumor-immune system interactions. Part two further examined the role of the host, and in this…

Part one of this four-part series looked at how host, tumor, and environmental factors shape tumor-immune system interactions. In the next few blogs, we will consider how each of these…

President Jimmy Carter announced this spring that he no longer needed treatments for the metastatic melanoma found in his brain–after treatment with pembrolizumab (Keytruda, Merck), his physicians could no longer…

[caption id="attachment_146" align="alignright" width="300"] NanoString at ASH 2016.[/caption] We attended the annual meeting of the American Society of Hematology (ASH) in San Diego. The convention center was abuzz with scientists…

What do we already know about tumor-immune system interactions, and how can this information be used to help guide us toward the best therapeutic choice? That is exactly the question…

Looking beyond anti-PD1/PDL1 with combination therapy and gene signature testing

Immuno-oncology (IO) focuses on harnessing the tremendous power of the human immune system to detect and destroy cancer cells.